Researchers conducted a double-blind, randomized placebo-controlled clinical trial that included 94 patients treated at St. Jude Children’s Research Hospital in Chicago and at the Royal Children’s Hospital in Melbourne, Australia.
The patients were receiving antibiotics for central line-associated bloodstream infections. They were randomly assigned to a six-month schedule of central line treatment with either 70 percent ethanol solution or saline solution.
The study shows 44 percent of patients in both groups developed new or recurring bloodstream infections or required surgical replacement of central line catheters. Also, 58 percent of patients in the ethanol group needed blood thinners versus 33 percent in the saline group.
“Based on these results, ethanol-lock therapy should not be routinely used in children with cancer or hematologic disorders,” said study first author Joshua Wolf, an assistant member of St. Jude’s infectious diseases department.
More articles on healthcare quality:
Medical workers complete experimental vaccination of Ebola contacts in the Congo
Second body found at San Francisco hospital in 1 week
Preventable deaths from lack of quality care cost trillions each year
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
